Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BB 882; DO 6; GR 167089; Lexipafant - Vernalis; Zacutex

Latest Information Update: 16 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vernalis
  • Developer DevCo Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Antiplatelets; Branched-chain amino acids; Imidazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Platelet activating factor inhibitors; Platelet activating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cognition disorders; Neurological disorders; Pancreatitis; Reperfusion injury
  • Discontinued Arrhythmias; Asthma; Ischaemic heart disorders; Multiple sclerosis

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 23 Mar 2004 Lexipafant is available for licensing (http://www.devcopharma.com)
  • 23 Mar 2004 Clinical data from a media release have been added to the pharmacokinetics section
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top